Third trial of Sputnik Five approved, 1500 to be tested in third phase

- The vaccine is being developed in Russia

New Delhi / Hyderabad Dt. 16 2021 Saturday

The third trial of Corona's third vaccine, Sputnik Five, was approved by the Drug Controller General of India (DCGI).

The vaccine is being developed in Russia and was being developed in Dr. Reddy's laboratory in India. DCGI approved her third trial.

Earlier, we were allowed to administer the Pfizer and Home Serum Institute of India vaccines there and from today, the vaccination will start in different cities and rural areas of different states of the country.

The Sputnik Five vaccine is ready at Dr Reddy's laboratory in Hyderabad and according to Dr Reddy, the vaccine will be given to 1,500 volunteers in the third trial.

According to the Centre's health department, there are currently 200 companies in the world developing corona vaccines. Thirty companies are from India. So far, however, Covishield of Serum Institute and Covexin of Bharat Biotech have been approved by the Government of India and these two vaccines are scheduled to start from today. The Zykovid vaccine is currently in the trial phase in the state of Gujarat. Now Dr Reddy's vaccine had also reached the trial stage.

A study of Dr Reddy's second trial report was conducted by the Data and Security Monitoring Board before allowing the third phase trial of the vaccine. After being satisfied, Dr. Reddy's vaccine was allowed for a third trial.

JV Prasad, co-chairman of Dr Reddy's laboratory, said the clinical trial was a milestone. We will start the third phase trial this month. We hope to develop a safe vaccine for the people of India.

Dr. Reddy's laboratory reached an understanding with RDIF in September last year regarding the Sputnik Five vaccine. Under the agreement, Dr Reddy's laboratory acquired the rights to trial and distribute the Sputnik Five vaccine in India.